---
title: "Cumberland outlines $100M Apotex deal while shifting to development-focused strategy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285323856.md"
description: "Cumberland Pharmaceuticals has announced a $100 million deal with Apotex to acquire its portfolio of marketed products, pending shareholder approval. The company plans to shift its focus to developing new products following the transaction. In Q1 2026, Cumberland reported a net loss of approximately $3.3 million, with total operating expenses of $12.3 million. The company achieved positive cash flow from operations of $387,000. Management sentiment remains slightly positive despite a shift from growth targets to a focus on strategic repositioning."
datetime: "2026-05-06T06:45:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285323856.md)
  - [en](https://longbridge.com/en/news/285323856.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285323856.md)
---

# Cumberland outlines $100M Apotex deal while shifting to development-focused strategy

Earnings Call Insights: Cumberland Pharmaceuticals (CPIX) Q1 2026 Management View "We're pleased to report continued momentum in 2026 as we're off to an excellent start with FDA approval for expanded Caldolor labeling, initiation of our sales promotional efforts in support of Talicia, the first shipment of Vibativ to China and FDA clearance of the ...

### Related Stocks

- [CPIX.US](https://longbridge.com/en/quote/CPIX.US.md)

## Related News & Research

- [2 Ways to Play the Big Pharma Patent Cliff](https://longbridge.com/en/news/286553222.md)
- [What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders](https://longbridge.com/en/news/286674743.md)
- [Aspire Biopharma Announces 1-for-30 Reverse Stock Split](https://longbridge.com/en/news/286469924.md)
- [Should You Be Adding Daewoong Pharmaceutical (KRX:069620) To Your Watchlist Today?](https://longbridge.com/en/news/286824214.md)
- [Sanofi says rare lung disease drug outperforms standard care in trial](https://longbridge.com/en/news/286810610.md)